摘要
Microarray-based classifiers and associated signature genes generated from various platforms are abundantly reported in the literature; however, the utility of the classifiers and signature genes in cross-platform prediction applications remains largely uncertain. As part of the MicroArray Quality Control Phase II (MAQC-II) project, we show in this study 80-90% cross-platform prediction consistency using a large toxicogenomics data set by illustrating that: (1) the signature genes of a classifier generated from one platform can be directly applied to another platform to develop a predictive classifier; (2) a classifier developed using data generated from one platform can accurately predict samples that were profiled using a different platform. The results suggest the potential utility of using published signature genes in cross-platform applications and the possible adoption of the published classifiers for a variety of applications. The study reveals an opportunity for possible translation of biomarkers identified using microarrays to clinically validated non-array gene expression assays.
| 源语言 | 英语 |
|---|---|
| 页(从-至) | 247-257 |
| 页数 | 11 |
| 期刊 | Pharmacogenomics Journal |
| 卷 | 10 |
| 期 | 4 |
| DOI | |
| 出版状态 | 已出版 - 8月 2010 |
| 已对外发布 | 是 |
学术指纹
探究 'Consistency of predictive signature genes and classifiers generated using different microarray platforms' 的科研主题。它们共同构成独一无二的学术指纹。引用此
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver